These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group. Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442 [Abstract] [Full Text] [Related]
3. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Grosse-Bley A, Eis-Hübinger AM, Kaiser R, Oldenburg J, Brackmann HH, Schwarz TF, Schneweis KE. Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623 [Abstract] [Full Text] [Related]
4. [Prevalence of anti-human parvovirus B19 IgG antibody among blood donors in Jilin province]. Wei Q, Li Y, Wang JW, Wang H, Qu JG, Hung T. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):60-2. PubMed ID: 16816866 [Abstract] [Full Text] [Related]
5. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S. Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688 [Abstract] [Full Text] [Related]
6. Parvovirus B19 may have a role in the pathogenesis of juvenile idiopathic arthritis. Gonzalez B, Larrañaga C, León O, Díaz P, Miranda M, Barría M, Gaggero A. J Rheumatol; 2007 Jun; 34(6):1336-40. PubMed ID: 17477467 [Abstract] [Full Text] [Related]
7. Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis. Weissbrich B, Süss-Fröhlich Y, Girschick HJ. Arthritis Res Ther; 2007 Jun; 9(4):R82. PubMed ID: 17760961 [Abstract] [Full Text] [Related]
10. [Parvovirus B19 infection in patients with congenital blood coagulation disorders]. Aguilar Franco C, Lucía Cuesta JF, Ferrer Torres J, Omeñaca Teres M. Med Clin (Barc); 1997 May 03; 108(17):641-6. PubMed ID: 9312580 [Abstract] [Full Text] [Related]
11. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area. Parsyan A, Addo-Yobo E, Owusu-Ofori S, Akpene H, Sarkodie F, Allain JP. Transfusion; 2006 Sep 03; 46(9):1593-600. PubMed ID: 16965589 [Abstract] [Full Text] [Related]
12. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa. Rubinstein R, Karabus CD, Smuts H, Kolia F, Van Rensburg EJ. Haemophilia; 2000 Mar 03; 6(2):93-7. PubMed ID: 10781195 [Abstract] [Full Text] [Related]
13. Seroepidemiology of human parvovirus B19 in Taiwan. Lin KH, You SL, Chen CJ, Wang CF, Yang CS, Yamazaki S. J Med Virol; 1999 Feb 03; 57(2):169-73. PubMed ID: 9892403 [Abstract] [Full Text] [Related]
14. [Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey]. Türk Dağı H, Ozdemir M, Baykan M, Baysal B. Mikrobiyol Bul; 2010 Jul 03; 44(3):467-72. PubMed ID: 21063997 [Abstract] [Full Text] [Related]
19. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY. Transfusion; 2005 Jun 03; 45(6):1003-10. PubMed ID: 15935000 [Abstract] [Full Text] [Related]
20. Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution. Canales MA, Pinilla J, Mateos P, Martínez Zapico R, Alvarez T, Jiménez VM, Quintana M, Villar A, Hernández Navarro F, Magallón M. Vox Sang; 1998 Jun 03; 74(4):260-1. PubMed ID: 9691409 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]